Literature DB >> 8031347

Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome.

R G Spragg1, N Gilliard, P Richman, R M Smith, R D Hite, D Pappert, B Robertson, T Curstedt, D Strayer.   

Abstract

In an attempt to restore functional surfactant to the lungs of patients with the adult respiratory distress syndrome (ARDS), we have treated six patients within the first 2 days of the onset of ARDS with a single dose of hydrophobic components of porcine surfactant. Surfactant (4 g in 50 ml) delivered via a bronchoscope in aliquots to each of the lobar bronchi was well tolerated and caused a modest transient improvement in gas exchange. No significant changes in chest radiograph or lung compliance were detected. Analysis of bronchoalveolar lavage (BAL) fluid showed no change in albumin, alpha-1-proteinase inhibitor specific activity, or cell count. Bronchoalveolar lavage phospholipid concentrations were elevated 3 h after surfactant administration relative to preadministration levels and fell by 24 h. In addition, in two patients we found reduced inhibition of surfactant function in BAL after surfactant replacement. These observations suggest a role for surfactant replacement in the treatment of patients with ARDS and support the need for continuing investigation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8031347     DOI: 10.1378/chest.105.1.195

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  24 in total

Review 1.  Acute respiratory distress syndrome: pharmacological treatment options in development.

Authors:  R D Hite; P E Morris
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Transfusion-related acute lung injury treated with surfactant in a neonate.

Authors:  T J Wu; R J Teng; K I Tsou Yau
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

3.  New targets for surfactant replacement therapy: experimental and clinical aspects.

Authors:  B Robertson
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-07       Impact factor: 5.747

4.  Nebulisation of surfactants in an animal model of neonatal respiratory distress.

Authors:  T F Fok; M al-Essa; M Dolovich; F Rasid; H Kirpalani
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-01       Impact factor: 5.747

Review 5.  The American-European Consensus Conference on ARDS, part 2. Ventilatory, pharmacologic, supportive therapy, study design strategies and issues related to recovery and remodeling.

Authors:  A Artigas; G R Bernard; J Carlet; D Dreyfuss; L Gattinoni; L Hudson; M Lamy; J J Marini; M A Matthay; M R Pinsky; R Spragg; P M Suter
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

6.  Surfactant replacement therapy in acute respiratory distress syndrome from viral pneumonia.

Authors:  G Putz; C Hörmann; W Koller; G Schön
Journal:  Intensive Care Med       Date:  1996-06       Impact factor: 17.440

Review 7.  Prevention and therapy of the adult respiratory distress syndrome.

Authors:  B Temmesfeld-Wollbrück; D Walmrath; F Grimminger; W Seeger
Journal:  Lung       Date:  1995       Impact factor: 2.584

8.  The acute respiratory distress syndrome: definitions, severity and clinical outcome. An analysis of 101 clinical investigations.

Authors:  P Krafft; P Fridrich; T Pernerstorfer; R D Fitzgerald; D Koc; B Schneider; A F Hammerle; H Steltzer
Journal:  Intensive Care Med       Date:  1996-06       Impact factor: 17.440

9.  Exposure of the hydrophobic components of porcine lung surfactant to oxidant stress alters surface tension properties.

Authors:  N Gilliard; G P Heldt; J Loredo; H Gasser; H Redl; T A Merritt; R G Spragg
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

Review 10.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.